The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 317.50
Bid: 318.00
Ask: 320.50
Change: 2.50 (0.79%)
Spread: 2.50 (0.786%)
Open: 315.00
High: 323.00
Low: 312.00
Prev. Close: 315.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Oxford Biomedica PLC - Block Listing Return

3 Jul 2023 07:00

RNS Number : 6510E
Oxford Biomedica PLC
03 July 2023
 

For Immediate Release 3 July 2023

OXFORD BIOMEDICA PLC

BLOCK LISTING RETURN

Name of applicant:

OXFORD BIOMEDICA PLC

Name of scheme:

2015 Employee Share Option Scheme

Period of return:

From:

1 January 2023

To:

30 June 2023

Balance of unallotted securities under scheme(s) from previous return:

331,574

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

22,148

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

309,426

 

 

Name of applicant:

OXFORD BIOMEDICA PLC

Name of scheme:

2015 Long Term Incentive Plan

Period of return:

From:

1 January 2023

To:

30 June 2023

Balance of unallotted securities under scheme(s) from previous return:

339,319

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

300,000

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

196,342

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

442,977

 

 

 

Name of applicant:

OXFORD BIOMEDICA PLC

Name of scheme:

2015 Deferred Bonus Plan

Period of return:

From:

1 January 2023

To:

30 June 2023

Balance of unallotted securities under scheme(s) from previous return:

202,445

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

100,000

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

6,173

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

296,272

 

 

 

Name of applicant:

OXFORD BIOMEDICA PLC

Name of scheme:

Sharesave Scheme

Period of return:

From:

1 January 2023

To:

30 June 2023

Balance of unallotted securities under scheme(s) from previous return:

331,484

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

100,000

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

91,731

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

339,753

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRFLFSRDVIFIIV
Date   Source Headline
6th Jun 20191:08 pmRNSAxovant update on 1st cohort of Sunrise-PD trial
6th Jun 201911:39 amRNSHolding(s) in Company
5th Jun 201912:06 pmRNSHoldings in Company
4th Jun 20195:38 pmRNSHoldings in Company
4th Jun 20199:59 amRNSTotal Voting Rights
3rd Jun 20196:06 pmRNSHolding(s) in Company
3rd Jun 201910:31 amRNSTotal Voting Rights
29th May 20196:19 pmRNSExercise of Subscription Option by Novo Holdings
29th May 20191:06 pmRNSResult of AGM
28th May 20197:00 amRNSStrategic Investment by Novo Holdings A/S
23rd May 20196:04 pmRNSDirector Dealings / Market Share Purchase
2nd May 20192:53 pmRNSLong Term Incentive Plan Option Grant
1st May 201912:52 pmRNSREPLACEMENT: Total Voting Rights
1st May 201911:33 amRNSTotal Voting Rights
30th Apr 20195:38 pmRNSHoldings in Company
30th Apr 20191:35 pmRNSOxford Biomedica to present at the ASGCT
30th Apr 20191:15 pmRNSAxovant doses second cohort of AXO-Lenti-PD
25th Apr 20193:38 pmRNSDirector Dealings / Market Share Purchase
23rd Apr 20191:47 pmRNSDeferred Bonus Plan and LTIP Option Grants
23rd Apr 201911:38 amRNSDirector Dealings / Market Share Transactions
18th Apr 20195:33 pmRNSExercise of warrants
18th Apr 20197:00 amRNSAnnual Report and Accounts & AGM Notification
1st Apr 201911:40 amRNSTotal Voting Rights
26th Mar 201912:57 pmRNSDirector Dealings / Market Share Purchase
26th Mar 20198:25 amRNSJapanese approval of Kymriah® (tisagenlecleucel)
14th Mar 20197:00 amRNSPreliminary Results
12th Mar 20197:00 amRNSOXB announces R&D collaboration with Microsoft
11th Mar 201910:38 amRNSAxovant's update on Phase 2 trial of AXO-Lenti-PD
1st Mar 20199:30 amRNSTotal Voting Rights
25th Feb 201912:23 pmRNSDirector Dealings / Market Share Purchase
8th Feb 20197:00 amRNSNotice of Results
7th Feb 201911:49 amRNSDirector/PDMR Shareholding
7th Feb 20199:22 amRNSUpdate on programmes outlicensed to Sanofi
6th Feb 201911:00 amRNSDirector Dealings / Market Share Transactions
5th Feb 201910:22 amRNSDirector Dealings / Market Share Purchase
1st Feb 201910:00 amRNSTotal Voting Rights
24th Jan 201911:20 amRNSDirector Dealings / Market Share Purchase
3rd Jan 201912:20 pmRNSBlock listing Interim Review
2nd Jan 201910:17 amRNSTotal Voting Rights
21st Dec 20181:16 pmRNSDirector Dealings / Market Share Purchase
6th Dec 20184:11 pmRNSAxovant FDA meeting feedback
3rd Dec 20189:53 amRNSTotal Voting Rights
3rd Dec 20187:00 amRNSLonger term Kymriah efficacy and safety data
23rd Nov 201810:41 amRNSDirector Dealings
23rd Nov 20187:00 amRNSOxford Biomedica form digital framework initiative
9th Nov 20187:00 amRNSBlock listing application
1st Nov 20182:41 pmRNSTotal Voting Rights
25th Oct 20187:00 amRNSAxovant Doses First Patient with AXO-Lenti-PD
22nd Oct 20184:39 pmRNSDirector Dealings / Market Share Purchase
5th Oct 20187:00 amRNSDetails of alliance with Orchard Therapeutics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.